Aspirin/ramipril/simvastatin

Drug Profile

Aspirin/ramipril/simvastatin

Alternative Names: Acetylsalicylic-acid/ramipiril/simvastatin; Cardiovascular Polypill; Polypill - Ferrer

Latest Information Update: 18 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferrer
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Heterocyclic bicyclo compounds; Naphthalenes; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiovascular disorders

Most Recent Events

  • 11 Jul 2011 Ferrer Internacional terminates a phase II pharmacodynamic trial in Cardiovascular disorders in the US (NCT01004705)
  • 22 Oct 2009 Phase-II clinical trials in Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top